Replies to post #5194 on Arbutus Biopharma Corporation (ABUS)

[DewDiligence]

ABUS 1Q19 results:

https://investor.arbutusbio.com/news-releases/news-release-details/arbutus-reports-first-quarter-2019-financial-results-and

3/31/19 cash was $110.6M. 1Q19 operating cash burn was $16.5M, slightly below the run rate of the company’s guidance for 2019 cash burn of $70-75M.

During 1Q19, ABUS sold $2.6M of stock under its ATM facility. As of 3/31/19, there were 86M fully-diluted shares.